NCT05527119

Brief Summary

Malaria remains the world's leading parasitic endemic. Almost half of the world's population lives in endemic areas. Many at-risk people in African countries remain without access to malaria control. Malaria kills approximately 400,000 people each year, most of whom are children under the age of 5 in Africa. Since 2005, an increasing number of Plasmodium vivax infections have been observed in Duffy-negative populations in South America and Africa, calling into question the essential role of the PvDBP-DARC interaction. The objective of the investigators is therefore to study and understand the invasion pathways used by Plasmodium vivax in Duffy-negative subjects.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Mar 2022

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 11, 2022

Completed
6 months until next milestone

First Submitted

Initial submission to the registry

August 30, 2022

Completed
3 days until next milestone

First Posted

Study publicly available on registry

September 2, 2022

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 11, 2023

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 11, 2023

Completed
Last Updated

November 8, 2023

Status Verified

November 1, 2023

Enrollment Period

1.3 years

First QC Date

August 30, 2022

Last Update Submit

November 7, 2023

Conditions

Plasmodium Vivax

Keywords

MalariaMalaria, VivaxPvDBP-DARC interactionPlasmodium vivaxDuffy-negativeDuffy Binding ProteinPvDBPDuffy Antigen Receptor for Chemokines

Outcome Measures

Primary Outcomes (1)

  • Number of blood samples tested (phenotype and genotype).

    2 months later

Eligibility Criteria

Age18 Years+
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

\- Major subjects with malaria and willing to have their blood samples analyzed for this research

You may qualify if:

  • Major subjects
  • with malaria and willing to have their blood samples analyzed for this research

You may not qualify if:

  • Subjects refusing to participate in the study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Service de Laboratoire de Parasitologie et Mycologie Médicale-PTM - CHU de Strasbourg - France

Strasbourg, 67091, France

Location

MeSH Terms

Conditions

Malaria, VivaxMalaria

Condition Hierarchy (Ancestors)

Protozoan InfectionsParasitic DiseasesInfectionsMosquito-Borne DiseasesVector Borne Diseases

Study Officials

  • Didier MENARD, MD, PhD

    Service Laboratoire de Parasitologie et Mycologie Médicale-PTM - CHU de Strasbourg - France

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 30, 2022

First Posted

September 2, 2022

Study Start

March 11, 2022

Primary Completion

July 11, 2023

Study Completion

September 11, 2023

Last Updated

November 8, 2023

Record last verified: 2023-11

Locations

FR(1)